利妥昔单抗治疗自身免疫性大疱病

Rituximab Treatment of Autoimmune Bullous Disease

自身免疫性大疱性皮肤病是一类少见的重症疾病,主要包括天疱疮和类天疱疮。近年来,多种生物制剂和靶向治疗陆续应用于自身免疫性大疱性皮肤病。目前在美国与欧洲,利妥昔单抗已作为中重度寻常型天疱疮的一线治疗方案。本文将对利妥昔单抗治疗自身免疫性大疱病的作用机制、治疗方案以及安全性做一概述。

Autoimmune bullous disease(AIBD)in eluding pemphigus and pemphigoid is rare and severe.In recent years,a variety of biological agents and targeted therapy have been used in AIBD.At present,rituximab has been used as the first-line treatment for moderate to severe pemphigus vulgaris in the United States and Europe.In this paper,the mechanism,treatment regime ns,and safety of rituximab therapy were summarized.